Company Insights

ARCT customer relationships

Explore interactive graphBrowse insights index
ARCT customer relationship map

Arcturus Therapeutics (ARCT): Customer map, concentration risks, and commercial posture

Arcturus Therapeutics operates as an RNA medicines company that monetizes through a mix of license and collaboration agreements, government cost‑reimbursement contracts, and commercial product sales in select markets. The business generates the bulk of its near‑term revenue by licensing its STARR® self‑amplifying mRNA platform and delivering mRNA drug substance/product under exclusive partner deals, while government awards fund specific pandemic programs and limited direct product sales have begun in Japan. For investors, the company is a collaborator‑and‑licensee business with high revenue concentration and a hybrid commercialization path that shifts revenue recognition across licensing, supply, and milestone streams. Learn more about how we surface commercial counterparty signals at https://nullexposure.com/.

What the customer footprint tells you about the business model

Arcturus’s customer relationships show a contracting posture tilted toward long‑term exclusive licensing and large sponsored government programs, not high‑volume direct retail distribution. Key features:

  • High concentration: One partner dominates reported revenue, creating a single‑counterparty dependency that drives both upside and execution risk.
  • Licensing + supply structure: Core commercial monetization is an exclusive global license with performance obligations that are recognized both over time and at a point in time (the vaccine license element).
  • Government funding for platform R&D: Federal cost‑reimbursement contracts underwrite platform advancement for pandemic preparedness and flow into accounts receivable.
  • Regional commercialization footholds: Japan and Europe are the first commercial markets, with distribution executed through regional partners and licensees.

These company‑level signals come from the 2024 Form 10‑K disclosures and subsequent investor communications and press reports.

Every material customer relationship (what each partner does for Arcturus)

CSL / CSL Seqirus — the revenue engine and licensee

CSL Seqirus is Arcturus’s principal commercial partner; CSL accounted for the overwhelming majority of 2024 revenue and holds an exclusive global license to Arcturus’s mRNA technology. According to Arcturus’s 2024 Form 10‑K, CSL represented 91% of total revenue for the year ended December 31, 2024, and the collaboration grants CSL exclusive global rights to STARR® and LUNAR® plus manufacturing process know‑how; the agreement contains five performance obligations with the vaccine license recognized at a point in time. (Arcturus 2024 Form 10‑K; FY2024)

BARDA (Biomedical Advanced Research and Development Authority) — government development sponsor

BARDA is a large government cost‑reimbursement contract counterparty funding Arcturus’s samRNA pandemic influenza program and is a dominant accounts‑receivable source. The 2024 Form 10‑K notes a BARDA‑funded Phase 1 dosing event in December 2024, and the filing also records BARDA as 60% of total accounts receivable as of December 31, 2024. Independent reporting documents a $63.2 million award announced in 2022 for development of a self‑amplifying mRNA influenza vaccine. (Arcturus 2024 Form 10‑K; GlobalBiodefense, Aug 2022)

Department of Health and Human Services / ASPR — contracting vehicle cited

Federal support to the BARDA program is delivered through HHS/ASPR contracting structures and contract number disclosures. Public reporting tied the BARDA award to the Office of the Assistant Secretary for Preparedness and Response and lists contract identifiers used for the federal award. (GlobalBiodefense, Aug 2022)

Meiji Seika Pharma — Japan commercialization and distributor

Meiji Seika Pharma handles distribution in Japan and filed NDA updates for the localized vaccine presentations that enabled commercial launches. Arcturus investor calls and press releases indicate Meiji Seika filed applications with Japan’s PMDA for the lyophilized two‑dose presentation and the seasonal COVID variant update, and Meiji Seika is set to distribute the updated vaccine in Japan as part of the commercialization arrangement. (Arcturus Q2 2025 earnings call; PR Newswire/BioSpace, FY2024–FY2025)

Vinbiocare / Vinbiocare Biotechnology Joint Stock Company — licensed manufacturing and royalty partner in APAC

Vinbiocare is a regional licensee and manufacturing customer that pays for mRNA drug substance and royalties on vaccines produced in Vietnam. Arcturus disclosed that Vinbiocare accounted for material revenue in earlier periods (about 12% of revenue for the year ended Dec 31, 2022) and press coverage describes a collaboration where Vinbiocare purchases drug substance and pays royalties for locally produced vaccine. (Arcturus 2024 Form 10‑K; Biospectrum Asia, FY2021)

Janssen Pharmaceuticals (Johnson & Johnson) — historical research collaboration

Janssen entered a research collaboration and worldwide license agreement with Arcturus focused on RNA medicines; this is a legacy R&D partnership announced in 2017. The strategic collaboration and license was publicly announced via press release and forms part of Arcturus’s earlier industry collaborations. (GlobeNewswire, Oct 2017)

ARCALIS (株式会社ARCALIS) — Japanese CDMO licensee for manufacturing scale‑up

ARCALIS licensed Arcturus’s mRNA manufacturing technology to establish a CDMO capability in Japan intended to supply Arcturus R&D and commercial needs. Japanese trade reporting describes ARCALIS acquiring a license to Arcturus’s mRNA manufacturing methods and targeting cGMP supply in 2023 as a regional production node. (JETRO report, FY2022)

Constraints and what they reveal about execution risk and runway

  • Contract type — licensing dominant: The CSL collaboration is structured as a global exclusive license, with multiple performance obligations and mixed revenue recognition. This positions Arcturus as a technology licensor and supplier rather than a broad direct sales organization. (10‑K disclosures on the CSL Collaboration Agreement)
  • Counterparty type — government participation is material: BARDA cost‑reimbursement funding is a clear non‑dilutive development funding source and creates concentrated receivable exposure tied to government program milestones. (10‑K evidence and BARDA award reporting)
  • Geography — APAC and EMEA commercialization start: Product sales began in Japan (KOSTAIVE launched Oct 2024) and the company is pursuing European approvals, making APAC and EMEA initial commercial focus areas rather than the U.S. retail channel. (10‑K + earnings commentary)
  • Materiality — critical customer concentration: CSL’s 91% share of 2024 revenue is a structural concentration that makes Arcturus’s near‑term financials highly dependent on partner execution and remaining amortization of upfronts. (10‑K revenue disclosure)
  • Relationship maturity — active, mixed stage: Relationships span active commercial distribution (Japan), clinical development (BARDA and CSL trials), and legacy research licenses (Janssen), indicating a portfolio of mature partner contracts and active development programs. (10‑K; Q2 2025 investor commentary)

Mid‑article action: to explore these counterparty signals in a unified view, visit https://nullexposure.com/ for a consolidated customer risk profile.

Investor implications — upside, risks, and what to watch next

  • Upside: Exclusive global licensing to CSL provides an accelerated commercial pathway and near‑term revenue visibility through amortization and supply agreements; government awards reduce near‑term cash burn tied to platform development.
  • Key risks: Extreme customer concentration (CSL) creates single‑counterparty exposure; government awards and accounts receivable concentration (BARDA at 60% of A/R) produce execution and collection dependencies; arbitration and CSL‑related write‑downs referenced in filings highlight commercial and regulatory uncertainty. (10‑K; TradingView/press summaries)
  • Watchables: cadence of CSL supply agreements and amortization schedules, BARDA milestone payments and contracting updates, Meiji Seika distribution performance in Japan, and any arbitration outcomes tied to the CSL collaboration.

Bottom line and next steps

Arcturus is a license‑and‑partner commercial model with government program support and early regional product sales. The company’s near‑term fortunes are tightly linked to CSL Seqirus and BARDA, making partnership execution the central investment thesis for both upside and downside. For a deeper cross‑counterparty risk assessment and to monitor material changes across Arcturus’s partner set, review our coverage at https://nullexposure.com/.

Key takeaway: investors should treat ARCT as a collaborator‑dependent commercial story — high upside from successful partner commercialization and significant concentration risk until revenue diversity improves.